Bain Capital's Pagliuca Weighs In on AI's Impact on Software Valuations and Biotech Innovation

The private equity firm's senior advisor discusses the divergent effects of AI on different industries.

Feb. 4, 2026 at 10:39am

Got story updates? Submit your updates here. ›

According to Steve Pagliuca, Senior Advisor to Bain Capital and co-owner of the Boston Celtics, the intersection of artificial intelligence and financial strategy is rapidly reshaping investment landscapes. While AI is challenging software valuations, it is also accelerating innovation in the biotechnology sector, as evidenced by Bain Capital's investment in Maven Bio, an AI-powered drug discovery startup.

Why it matters

Pagliuca's insights provide a nuanced view of AI's transformative potential, recognizing its disruptive impact on some industries while also highlighting the opportunities it presents for innovation and growth in others. As a senior advisor at a major private equity firm, Pagliuca's perspective offers valuable industry insights on how technological advancements are reshaping investment strategies and market dynamics.

The details

Pagliuca highlighted the divergent impact of AI on software valuations versus its accelerating influence on the biotechnology industry. While AI is posing challenges for software valuations, Bain Capital's investment in Maven Bio, an AI-powered drug discovery startup, suggests a strategic bet on AI's ability to unlock efficiencies and accelerate innovation within the biopharmaceutical space. Maven Bio's AI agents are designed to assist with tasks such as screening potential drugs, benchmarking clinical performance, prioritizing opportunities, and building interactive landscape reports.

  • Pagliuca's comments were made during a Bloomberg TV appearance on January 22, 2026.
  • Bain Capital led a $3.1 million seed fundraise for Maven Bio on April 16, 2025.
  • The first half of 2025 saw significant M&A activity across eight key industries, including consumer products, software, healthcare, and biotechnology, according to data from IMAA-institute.org on September 16, 2025.

The players

Steve Pagliuca

Senior Advisor to Bain Capital and co-owner of the Boston Celtics.

Maven Bio

An AI-powered drug discovery startup that Bain Capital's family office led a $3.1 million seed fundraise for in April 2025.

Bain Capital

A major private equity firm that Pagliuca serves as a Senior Advisor for and has made strategic investments in companies like Maven Bio.

Got photos? Submit your photos here. ›

What they’re saying

“The intersection of artificial intelligence and financial strategy is rapidly reshaping investment landscapes.”

— Steve Pagliuca, Senior Advisor, Bain Capital (Bloomberg TV)

What’s next

As the interplay between AI and financial markets continues to evolve, Pagliuca's insights and Bain Capital's investment decisions will likely be closely watched by industry observers to gauge the long-term implications of these technological advancements.

The takeaway

Pagliuca's commentary highlights the nuanced and divergent impact of AI on different industries, with the technology posing challenges for software valuations while also presenting opportunities for innovation and growth in the biotechnology sector. Bain Capital's strategic investments, such as in Maven Bio, suggest a belief in AI's transformative potential, particularly in highly specialized domains like drug discovery.